Drugs / EXO 2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04491240 | Jul → Oct 2020 | COVID-19 | State-Financed Health Facility "Samara Regional Medical Center Dinasty" | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04602442 | Oct 2020 → Aug 2021 | COVID-19 | Olga Tyumina | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EXO 2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04491240 ↗ |
| Modality | Other / unclassified | “nanoparticles (exosomes) of the second type” NCT04491240 ↗ |
| Route | Inhaled | “Twice a day during 10 days inhalation of 3 ml special solution” NCT04491240 ↗ |